Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients

Authors: Daniel Brungs, Morteza Aghmesheh, Paul de Souza, Weng Ng, Wei Chua, Martin Carolan, Philip Clingan, Emma Healey, June Rose, Tameika Tubaro, Marie Ranson

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background/Aim

Right sided colon cancer (RsCC) is proposed to be a distinct disease entity to left sided colon cancer (LsCC). We seek to confirm primary tumour location as an independent prognostic factor in locoregional colorectal cancer.

Methods

All patients with stage I – III primary adenocarcinoma of colon were identified from the New South Wales (NSW) clinical cancer registry (2006–2013). Primary tumour location (RsCC vs LsCC) survival analyses were conducted using the Kaplan-Meier method, and adjusted hazard ratios for 5-year all-cause mortality (OS) and 5-year cancer specific mortality (CSS) were obtained using Cox proportional hazards regression.

Results

We identified 9509 patients including 5051 patients with RsCC and 4458 with LsCC. Patients with RsCC were more likely to be older, female, have a higher Charlson comorbidity index, and have worse tumour prognostic factors. In univariate analysis of all stages combined, those patients with RsCC had a worse overall survival (OS, HR 1.20 95% CI 1.11–1.29, p < 0.0001), although this was not significant in the multivariate analysis (HR 0.96 95% CI 0.89–1.04, p = 0.35). Stage I patients with RsCC had a trend to improved OS (multivariate HR 0.84 95% CI 0.69–1.01, p = 0.07) and a significantly improved CSS (multivariate HR 0.51 95% CI 0.35–0.75, p = 0.0006). In stage II patients with RsCC there was a significantly improved OS (multivariate HR 0.85 95% CI 0.75–0.98, p = 0.02) and CSS (multivariate HR 0.59 95% CI 0.45–0.78, p = 0.0002) compared to LsCC. In stage III patients, those with RsCC had a worse OS (multivariate HR 1.13 95% CI 1.01–1.26, p = 0.032) and a trend to worse CSS (multivariate HR 1.12 95% CI 0.94–1.33, p = 0.22).

Conclusions

Primary tumour location is an important prognostic factor in locoregional colon cancer with an effect that varies by stage. RsCC is associated with lower all-cause mortality in stage II, and higher all-cause mortality in stage III.
Appendix
Available only for authorised users
Literature
1.
go back to reference AIHW. Cancer in Australia: an overview 2014. Cancer series no 90. 2014;CAN 88. AIHW. Cancer in Australia: an overview 2014. Cancer series no 90. 2014;CAN 88.
2.
go back to reference Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88:261–6.CrossRefPubMed Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88:261–6.CrossRefPubMed
3.
go back to reference Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113:779–88.CrossRefPubMed Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113:779–88.CrossRefPubMed
4.
go back to reference Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut. 2005;54:374–84.CrossRefPubMedPubMedCentral Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut. 2005;54:374–84.CrossRefPubMedPubMedCentral
5.
go back to reference Hansen IO, Jess P. Possible better long-term survival in left versus right-sided colon cancer - a systematic review. Dan Med J. 2012;59:A4444.PubMed Hansen IO, Jess P. Possible better long-term survival in left versus right-sided colon cancer - a systematic review. Dan Med J. 2012;59:A4444.PubMed
6.
go back to reference Bilimoria KY, Palis B, Stewart AK, Bentrem DJ, Freel AC, Sigurdson ER, et al. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum. 2008;51:154–61.CrossRefPubMed Bilimoria KY, Palis B, Stewart AK, Bentrem DJ, Freel AC, Sigurdson ER, et al. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum. 2008;51:154–61.CrossRefPubMed
7.
go back to reference Weiss JM, Pfau PR, O'Connor ES, King J, LoConte N, Kennedy G, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol. 2011;29:4401–9.CrossRefPubMedPubMedCentral Weiss JM, Pfau PR, O'Connor ES, King J, LoConte N, Kennedy G, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol. 2011;29:4401–9.CrossRefPubMedPubMedCentral
8.
go back to reference Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53:57–64.CrossRefPubMed Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53:57–64.CrossRefPubMed
9.
go back to reference Warschkow R, Sulz MC, Marti L, Tarantino I, Schmied BM, Cerny T, et al. Better survival in right-sided versus left-sided stage I - III colon cancer patients. BMC Cancer. 2016;16:554.CrossRefPubMedPubMedCentral Warschkow R, Sulz MC, Marti L, Tarantino I, Schmied BM, Cerny T, et al. Better survival in right-sided versus left-sided stage I - III colon cancer patients. BMC Cancer. 2016;16:554.CrossRefPubMedPubMedCentral
10.
go back to reference Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 2008;15:2388–94.CrossRefPubMedPubMedCentral Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 2008;15:2388–94.CrossRefPubMedPubMedCentral
11.
go back to reference Suttie SA, Shaikh I, Mullen R, Amin AI, Daniel T, Yalamarthi S. Outcome of right- and left-sided colonic and rectal cancer following surgical resection. Colorectal Dis. 2011;13:884–9.CrossRefPubMed Suttie SA, Shaikh I, Mullen R, Amin AI, Daniel T, Yalamarthi S. Outcome of right- and left-sided colonic and rectal cancer following surgical resection. Colorectal Dis. 2011;13:884–9.CrossRefPubMed
12.
go back to reference Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P et al. Prognostic survival associated with left-sided vs right-sided Colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;3:211–9. Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P et al. Prognostic survival associated with left-sided vs right-sided Colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;3:211–9.
13.
go back to reference Fritz A PC, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al.: International classification of disease for oncology. Geneva: World Health Organization; 2000. Fritz A PC, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al.: International classification of disease for oncology. Geneva: World Health Organization; 2000.
14.
go back to reference Irvine KA, Moore EA. Linkage of routinely collected data in practice: the Centre for Health Record Linkage. Public Health Res Pract. 2015;25:e2541548.CrossRefPubMed Irvine KA, Moore EA. Linkage of routinely collected data in practice: the Centre for Health Record Linkage. Public Health Res Pract. 2015;25:e2541548.CrossRefPubMed
15.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed
16.
go back to reference Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288–94.CrossRefPubMed Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288–94.CrossRefPubMed
17.
go back to reference Jess P, Hansen IO, Gamborg M, Jess T. A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open. 2013;3 Jess P, Hansen IO, Gamborg M, Jess T. A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open. 2013;3
18.
go back to reference Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ, Zell JA. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 2009;52:1359–66.CrossRefPubMed Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ, Zell JA. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 2009;52:1359–66.CrossRefPubMed
19.
go back to reference Lykke J, Roikjaer O, Jess P. The relation between lymph node status and survival in stage I-III colon cancer: results from a prospective nationwide cohort study. Colorectal Dis. 2013;15:559–65.CrossRefPubMed Lykke J, Roikjaer O, Jess P. The relation between lymph node status and survival in stage I-III colon cancer: results from a prospective nationwide cohort study. Colorectal Dis. 2013;15:559–65.CrossRefPubMed
20.
go back to reference Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2000;355:1745–50.CrossRefPubMed Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2000;355:1745–50.CrossRefPubMed
21.
go back to reference Bhangu A, Kiran RP, Slesser A, Fitzgerald JE, Brown G, Tekkis P. Survival after resection of colorectal cancer based on anatomical segment of involvement. Ann Surg Oncol. 2013;20:4161–8.CrossRefPubMed Bhangu A, Kiran RP, Slesser A, Fitzgerald JE, Brown G, Tekkis P. Survival after resection of colorectal cancer based on anatomical segment of involvement. Ann Surg Oncol. 2013;20:4161–8.CrossRefPubMed
22.
go back to reference Seppala TT, Bohm JP, Friman M, Lahtinen L, Vayrynen VM, Liipo TK, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer. 2015;112:1966–75.CrossRefPubMedPubMedCentral Seppala TT, Bohm JP, Friman M, Lahtinen L, Vayrynen VM, Liipo TK, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer. 2015;112:1966–75.CrossRefPubMedPubMedCentral
23.
go back to reference Lee DW, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, et al. Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. Br J Cancer. 2013;108:1978–84.CrossRefPubMedPubMedCentral Lee DW, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, et al. Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. Br J Cancer. 2013;108:1978–84.CrossRefPubMedPubMedCentral
24.
go back to reference Distler P, Holt PR. Are right- and left-sided colon neoplasms distinct tumors? Dig Dis. 1997;15:302–311. Distler P, Holt PR. Are right- and left-sided colon neoplasms distinct tumors? Dig Dis. 1997;15:302–311.
25.
go back to reference Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.CrossRefPubMedPubMedCentral Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.CrossRefPubMedPubMedCentral
26.
go back to reference Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623–32.CrossRefPubMedPubMedCentral Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623–32.CrossRefPubMedPubMedCentral
27.
go back to reference Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/alliance N0147. J Natl Cancer Inst. 2014;106:dju228. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/alliance N0147. J Natl Cancer Inst. 2014;106:dju228.
28.
go back to reference Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology. 1996;110:682–7.CrossRefPubMed Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology. 1996;110:682–7.CrossRefPubMed
29.
go back to reference Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261–70.CrossRefPubMed Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261–70.CrossRefPubMed
30.
go back to reference Oh BY, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, et al. Prognostic factors in sporadic colon cancer with high-level microsatellite instability. Surgery. 2016;159:1372–81.CrossRefPubMed Oh BY, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, et al. Prognostic factors in sporadic colon cancer with high-level microsatellite instability. Surgery. 2016;159:1372–81.CrossRefPubMed
31.
go back to reference Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.CrossRefPubMedPubMedCentral Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.CrossRefPubMedPubMedCentral
32.
go back to reference Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A et al. Adjuvant fluorouracil, Leucovorin, and Oxaliplatin in stage II to III Colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33:4176-4187. Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A et al. Adjuvant fluorouracil, Leucovorin, and Oxaliplatin in stage II to III Colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33:4176-4187.
33.
go back to reference Heinemann V, Modest DP, Weikersthal LFv, Thomas Decker AK, Ursula Vehling-Kaiser S-EA-B, Tobias Heintges, Christian A. Lerchenmuller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Swantje Held, Clemens Albrecht Giessen, Andreas Jung, Thomas Kirchner, Sebastian Stintzing. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol. 2014;32:5s. Heinemann V, Modest DP, Weikersthal LFv, Thomas Decker AK, Ursula Vehling-Kaiser S-EA-B, Tobias Heintges, Christian A. Lerchenmuller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Swantje Held, Clemens Albrecht Giessen, Andreas Jung, Thomas Kirchner, Sebastian Stintzing. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol. 2014;32:5s.
Metadata
Title
Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients
Authors
Daniel Brungs
Morteza Aghmesheh
Paul de Souza
Weng Ng
Wei Chua
Martin Carolan
Philip Clingan
Emma Healey
June Rose
Tameika Tubaro
Marie Ranson
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3255-z

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine